Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin Add-On vs Opioids Alone for Neuropathic Cancer Pain
jRCTs031220569Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of mirogabalin in neuropathic cancer pain (NCP) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in pain NRS from enrollment to week 4. Started Mar 2023; status: completed.
02
Drugs
mirogabalin
03
Conditions
neuropathic cancer pain (NCP)
Beyond the preview
Go deeper on jRCTs031220569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220569.